Results
1 -
7 of
7Clinical Development of CHK1 Inhibitors, Targeting the DNA Damage Response for Anti-Cancer Therapy Targeting CHK1 for Cancer Therapy: Rationale, Progress and Prospects, Targeting the DNA Damage Response for Anti-Cancer Therapy A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients, BMC Cancer CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells, Journal of Hematology & Oncology The cell cycle checkpoint inhibitors in the treatment of leukemias, Journal of Hematology & Oncology ??H2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments, BMC Cancer